Assoc. Prof. Sandra Marinović Kulišić, MD, PhD

• Born in Split on April 17, 1976.
• Completed Zdravstvena škola in Split in 1994.
• Graduated from the University of Zagreb School of Medicine in 2001, having served as a student demonstrator in the Department of Pathology for four semesters.
• Completed postgraduate studies in Biology (Immunology and Physiology) at the Faculty of Science, University of Zagreb, in 2003.
• Passed the specialization exam in dermatovenerology in 2008 and has been employed at the Clinic for Skin and Venereal Diseases, KBC Zagreb, ever since.
• Earned a Master of Science degree in 2007 and defended a doctoral dissertation titled “The Role of Adhesion Molecules in Inflammatory and Healthy Skin” in 2010, obtaining a PhD in science.
• Published 5 works and 10 abstracts in Current Contents, 11 works in SCI-Expanded, 6 publications in PubMed, 38 conference presentations, and 35 educational texts.
• Attended additional training in phlebology at KBC Ljubljana and KB Dubrava in Zagreb. Completed the “Doppler Ultrasonographic Diagnostics of Vascular Diseases” course in 2007 and the “Phlebology School 1, 2, 3” courses at KBC Ljubljana in 2013.
• Actively participated in international professional gatherings on chronic venous diseases in Slovenia, England, Italy, and Austria.
• Appointed as a scientific associate in 2014 and promoted to senior scientific associate in 2020, specializing in clinical medical sciences.
• Became an honorary assistant professor in 2023 in the field of dermatovenerology.

Professional Training and Development

• Participation in the “Oxford European Wound Healing Summer School – Wound Healing: Old Problems-New Solutions,” Oxford, UK, August 4–7, 2010.
• Attendance at “Apparative Basisuntersuchungen (Arterial Doppler, AngE Tests, Digital Photoplethysmography, Acral Oscillography),” Graz, Austria, February 1, 2010.
• Attendance at “Forum Sclerotherapia,” Vienna, Austria, December 4, 2010.
• Participation in “Insights in Pediatric Allergology and Dermatology,” Berlin, Germany, September 29–30, 2011.
• Attendance at “Scleroterapia,” Florence, Italy, March 26–27, 2010.
• Participation in “Scleroterapia Ecoguidata,” Bologna, Italy, February 20, 2011.
• Attendance at “Scleroterapia,” Florence, Italy, March 23–24, 2012.
• Participation in “Venous Ultrasound Course,” London, UK, November 17, 2012.
• Attendance at the “6th Compact Micro-Sclerotherapy Training Course,” Munich, Germany, November 8, 2014.
• Attendance at “Scleroterapia,” Bologna, Italy, March 23–24, 2015.
• Participation in “Self-Management with Compression,” Melk, Austria, 2015.
• Attendance at “Scleroterapia,” Bologna, Italy, March 23–24, 2016.
• Participation in the “EADV Phlebology Course,” Bucharest, Romania, May 25–26, 2018.

• Completed a medical internship at the Fran Mihaljević Clinic in Zagreb and passed the state exam in 2002.
• Permanent member of the healthcare team at the Reference Center for Contact Allergy of the Ministry of Health of the Republic of Croatia and the outpatient department for allergology, immunology, and occupational skin diseases at the Clinic for Dermatovenerology, KBC Zagreb.
• Continuously involved in postgraduate teaching in dermatovenerology and led four professional training courses for medical professionals on chronic venous insufficiency from 2009 to 2012.
• Co-organized nine professional training courses for community health nurses, including workshops on chronic venous insufficiency.
• Engaged in the education of medical students, leading practical sessions in dermatovenerology, and contributing to postgraduate programs in dermatovenerology.
• External associate at the Croatian Catholic University, providing education in nursing studies.
• Awarded the “Borislav Nakić” scientific award by the Academy of Medical Sciences of Croatia in 2008 and received recognition from the Croatian Medical Association in 2011.

• Clinical Trial M16-045: A randomized, double-blind, placebo-controlled phase 3 study evaluating upadacitinib in adolescent and adult participants with moderate to severe atopic dermatitis.Role: Principal Investigator, Study Leader (July 2019).
• Clinical Trial CQGE031C2302: A multicenter, randomized, double-blind, active, and placebo-controlled study investigating the efficacy and safety of ligelizumab (QGE031) in treating chronic spontaneous urticaria in adolescents and adults with inadequate response to H1 antihistamines. Role: Principal Investigator, Study Leader (February 2020).
• Clinical Trial M16-046: A multicenter, randomized, double-blind, double-dummy, active-controlled phase 3b study comparing the safety and efficacy of upadacitinib to dupilumab in adult participants with moderate to severe atopic dermatitis. Role: Principal Investigator, Study Leader (February 2020).
• EFISS Study: Dose range determination and pilot study for the Expanded Study on Monitoring Reactions to Fragrance Components.Role: Principal Investigator, Study Leader (February 2020).
• Clinical Trial M19-850: An open-label extension phase 3b study evaluating upadacitinib in the treatment of adult participants with moderate to severe atopic dermatitis who completed the M16-046 study. Role: Principal Investigator, Study Leader (September 2020).

• Member of the Croatian Medical Association since 2001.
• Member of the Croatian Dermatovenereology Society of the Croatian Medical Association since 2003.
• Member of the Croatian Catholic Medical Society since 2004.
• Member of the Croatian Wound Association since 2007.
• Member of the European Wound Management Association since 2006.
• Member of the Italian Phlebology Society since 2010.
• Member of the Austrian Phlebology Society since 2010.
• Member of the UEMS Multidisciplinary Joint Committee on Wound Healing since 2016.
• Borislav Nakić Scientific Award of the Croatian Academy of Medical Sciences for the best scientific work in the field of medicine published in 2008.
• Recognition of the Croatian Medical Association in 2011